|
Scancell Holdings PLC on Monday reported a positive response in its ’Covidity’ trial, which aims to deliver needle-free injectable Covid vaccines. The Nottingham, England-based cancer immunotherapies developer said its Covid vaccine candidates induced neutralising antibodies in previously infected patients, previously vaccinated patients and ’naïve’ patients those never confirmed to have had Covid and who are not vaccinated. The needle-free injection is via a PharmaJet device, which delivers a vaccine or a medicine via a narrow fluid stream. PharmaJet is a Colorado, US-based medical technology company. Scancell added that the trial validates that ‘AvidiMab-modified immunotherapies boost immune responses and PharmaJet’s needle-free injection device is effective in delivering immunobody-generated drug candidates.’ Chief Executive Officer Lindy Durrant said: ‘The success of a human trial demonstrating that an AvidiMab modified DNA vaccine, delivered via a needle free injection, can induce both T cell and antibody responses, with no safety concerns, is a pivotal proof point for Scancell’s clinical strategy. The company added that it will now seek a partner to progress the Covidity vaccine programme. Scancell shares were 5.0% higher at 19.17 pence each in London on Monday morning. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
